Ayomide Peter Akomolafe

Mr. Ayomide Peter Akomolafe

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2023 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
Gaber El-Saber BatihaGaber El-Saber Batiha
Gaber El-Saber Batiha
John Oluwafemi TeiboJohn Oluwafemi Teibo
John Oluwafemi Teibo
LWLamiaa Wasef
Lamiaa Wasef
Hazem ShaheenHazem Shaheen
Hazem Shaheen
Ayomide Peter AkomolafeAyomide Peter Akomolafe
Ayomide Peter Akomolafe
MPMarios Papadakis
Marios Papadakis
Lavandula species is a flowering plant that is common in Europe and across the Mediterranean. Lavender has many health benefits for humans. In addition to its use in herbal medicine, it is widely used in the fields of cosmetics, perfumes, foods, and aromatherapy. Google Scholar, PubMed, Scopus, and Web of Science were used to search for relevant material on the phytochemical ingredients, the pharmacologic effects of the ingredients, and the mechanism of action of the Lavandula species identified. These materials were reviewed in order to have access to important updates about the Lavandula species. Lavender as referred to in English contains essential oils, anthocyanins, phytosterols, sugars, minerals, coumaric acid, glycolic acid, valeric acid, ursolic acid, herniarins, coumarins, and tannins. It has been used to treat colic and chest ailments, worrisome headaches, and biliousness, and in cleaning wounds. It has antifungal, antibacterial, neurologic, antimicrobial, anti-parasitic, anti-diabetic, and analgesic effects among others. Lavandula species has prospects for various biological applications, especially with its dermatological application. Advances in drug development would enable characterization of various bioactive constituents; thus, its development and application can have a more positive impact on humanity. Here, we highlighted updated information on the history, distribution, traditional uses, phytochemical components, pharmacology, and various biological activities of Lavandula species.

6 March 2023 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
Gaber El-Saber BatihaGaber El-Saber Batiha
Gaber El-Saber Batiha
AAAli Esmail Al-Snafi
Ali Esmail Al-Snafi
MTMahdi M. Thuwaini
Mahdi M. Thuwaini
John Oluwafemi TeiboJohn Oluwafemi Teibo
John Oluwafemi Teibo
Hazem ShaheenHazem Shaheen
Hazem Shaheen
MPMarios Papadakis
Marios Papadakis
Morusalba is a fast-growing shrub or medium-sized tree with a straight, cylindrical trunk. Medicinally, whole plants, leaves, fruits, branches, and roots have been employed. Google Scholar, PubMed, Scopus, and Web of Science were used to search for relevant material on the phytochemical components and pharmacologic and mechanism of action of the Morus alba. This was reviewed to assess important updates about Morus alba. The fruits of Morus alba have traditionally been used as an analgesic, anthelmintic, antibacterial, anti-rheumatic, diuretic, hypotensive, hypoglycemia, purgative, restorative, sedative tonic, and blood stimulant. Various plant parts were used as a cooling, sedating, diuretic, tonic, and astringent agent to treat nerve disorders. The plant contained tannins, steroids, phytosterols, sitosterol, glycosides, alkaloids, carbohydrates, proteins, and amino acids, as well as saponins, triterpenes, phenolics, flavonoids, benzofuran derivatives, anthocyanins, anthraquinones, glycosides, vitamins, and minerals. Previous pharmacological research identified antimicrobial, anti-inflammatory, immunological, analgesic, antipyretic, antioxidant, anti-cancer, antidiabetic, gastrointestinal, respiratory, cardiovascular, hypolipidemic, anti-obesity, dermatological, neurological, muscular, and protecting effects. This study looked at Morus alba’s traditional uses, chemical components, and pharmacological effects.

25 August 2025 in Toxicon
Verified
Journal Article
Closed access
Solomon OwumiSolomon Owumi
Solomon Owumi
JCJoseph Chimezie
Joseph Chimezie
IBIdris O. Bello
Idris O. Bello
MOMoses Otunla
Moses Otunla
UAUche Arunsi
Uche Arunsi
OOOlatunde O. Owoeye
Olatunde O. Owoeye

18 February 2026 in Toxics
Verified
Journal Article
Open access
PDF file
Solomon OwumiSolomon Owumi
Solomon Owumi
EPEsther Mayowa Pius
Esther Mayowa Pius
HAHikmah Adeola Abdulganiyu
Hikmah Adeola Abdulganiyu
IAIFEOLUWA OLUWAJENYO ALABI
IFEOLUWA OLUWAJENYO ALABI
VEVictor Oladimeji Eso
Victor Oladimeji Eso
CAChima M. Amadi
Chima M. Amadi
Benign prostatic hyperplasia (BPH) is a significant health issue among ageing men, with ongoing research focused on elucidating its underlying mechanisms and improving experimental models. Testosterone Propionate (TP) is the first line of choice for the induction of BPH in experimental rodent models. However, TP’s controlled status as a Schedule III drug in the United States and a Class C drug in the UK presents challenges in obtaining TP for experimental use, giving preference to the sulpiride model since it is easily obtained as an alternative for the induction and study of BPH. A comprehensive literature search was conducted across multiple electronic databases, including PubMed/MEDLINE, Embase, and Web of Science. The primary PubMed search strategy included combinations of Medical Subject Headings (MeSH) and free-text terms: (“Benign prostatic hyperplasia induction” OR “and rodent models’’) AND (“Testosterone Propionate model”) AND (“sulpiride model”). Studies were included if they induced BPH (using testosterone or sulpiride models). Titles and abstracts were screened for relevance; eligible articles underwent full-text review, with data extracted thematically. No formal risk-of-bias scoring was used due to the narrative approach; instead, studies were appraised by design, rigor, plausibility, and evidence. This study reviewed published and publicly available data, so no ethical approval was required. Although both TP and sulpiride induce BPH via various mechanisms, this review provides a comparative analysis of these two commonly utilised models for studying BPH. In the TP approach, castrated rodents receive daily subcutaneous injections for 4 weeks, resulting in dihydrotestosterone (DHT)-mediated epithelial hyperplasia predominantly affecting the ventral prostate lobes. Conversely, the sulpiride model is non-invasive, employs intact animals treated with sulpiride, and induces hyperprolactinemia-mediated BPH via interactions with androgen and oestrogen receptor pathways that stimulate prostatic stromal and epithelial proliferation, particularly in the lateral and dorsal lobes, representing an alternative method. We also highlight the strengths and limitations of TP and sulpiride in replicating clinical symptoms and examine the toxicological effects of sulpiride on the kidney, testis, liver, and brain. We recommend the sulpiride model for the induction and studying of BPH, as it is readily accessible and closely mimics the pathogenesis of BPH in humans, unlike the TP model, which requires castration.
1

15 April 2026 in Toxicon
Verified
Journal Article
Closed access
Solomon OwumiSolomon Owumi
Solomon Owumi
TOTaye Precious Olabisi
Taye Precious Olabisi
JCJoseph Chimezie
Joseph Chimezie
VEVictor Oladimeji Eso
Victor Oladimeji Eso
OOOluwaseun M. Owolabi
Oluwaseun M. Owolabi
CIChioma E. Irozure
Chioma E. Irozure

7 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Solomon OwumiSolomon Owumi
Solomon Owumi
EPEsther Mayowa Pius
Esther Mayowa Pius
HAHikmah Adeola Abdulganiyu
Hikmah Adeola Abdulganiyu
IAIFEOLUWA OLUWAJENYO ALABI
IFEOLUWA OLUWAJENYO ALABI
VEVictor Oladimeji Eso
Victor Oladimeji Eso
CAChima M. Amadi
Chima M. Amadi
Background: Benign prostatic hyperplasia (BPH) is a significant health issue among ageing men, with ongoing research focused on elucidating its underlying mechanisms and improving experimental models. Testosterone Propionate (TP) is the first line of choice for the induction of BPH in experimental rodent models. However, TP's controlled status as a Schedule III drug in the United States and a Class C drug in the UK presents challenges in obtaining TP for experimental use, giving preference to the sulpiride model since it is easily obtained as an alternative for the induction and study of BPH. Method: A comprehensive literature search was conducted across multiple electronic databases, including PubMed/MEDLINE, Embase, and Web of Science. The primary PubMed search strategy included combinations of Medical Subject Headings (MeSH) and free-text terms: (“Benign prostatic hyperplasia induction” OR ‘’ and rodent models’’) AND (“Testosterone Propionate model” ) AND (“sulpiride model”). Studies were included if they induced BPH (using testosterone or sulpiride models). Titles and abstracts were screened for relevance; eligible articles underwent full-text review, with data extracted thematically. No formal risk-of-bias scoring was used due to the narrative approach; instead, studies were appraised by design, rigor, plausibility, and evidence. This study reviewed published and publicly available data, so no ethical approval was required. Results: Although both TP and sulpiride induce BPH via various mechanisms, this review provides a comparative analysis of these two commonly utilised models for studying BPH. In the TP approach, castrated rodents receive daily subcutaneous injections for 4 weeks, resulting in dihydrotestosterone (DHT)-mediated epithelial hyperplasia predominantly affecting the ventral prostate lobes. Conversely, the sulpiride model is non-invasive, employs intact animals treated with sulpiride, and induces hyperprolactinemia-mediated BPH via interactions with androgen and oestrogen receptor pathways that stimulate prostatic stromal and epithelial proliferation, particularly in the lateral and dorsal lobes, representing an alternative method. We also highlight the strengths and limitations of TP and sulpiride in replicating clinical symptoms and examine the toxicological effects of sulpiride on the kidney, testis, liver, and brain. Conclusions: we recommend the sulpiride model for the induction and studying of BPH, as it is readily accessible and closely mimics the pathogenesis of BPH in humans, unlike the TP model, which requires castration.